Suppr超能文献

测定肝病期间肠道通透性和细菌移位的方法。

Methods to determine intestinal permeability and bacterial translocation during liver disease.

作者信息

Wang Lirui, Llorente Cristina, Hartmann Phillipp, Yang An-Ming, Chen Peng, Schnabl Bernd

机构信息

Department of Medicine, University of California San Diego, La Jolla, CA, United States; Department of Medicine, VA San Diego Healthcare System, San Diego, CA, United States.

Department of Medicine, University of California San Diego, La Jolla, CA, United States.

出版信息

J Immunol Methods. 2015 Jun;421:44-53. doi: 10.1016/j.jim.2014.12.015. Epub 2015 Jan 13.

Abstract

Liver disease is often times associated with increased intestinal permeability. A disruption of the gut barrier allows microbial products and viable bacteria to translocate from the intestinal lumen to extraintestinal organs. The majority of the venous blood from the intestinal tract is drained into the portal circulation, which is part of the dual hepatic blood supply. The liver is therefore the first organ in the body to encounter not only absorbed nutrients, but also gut-derived bacteria and pathogen associated molecular patterns (PAMPs). Chronic exposure to increased levels of PAMPs has been linked to disease progression during early stages and to infectious complications during late stages of liver disease (cirrhosis). It is therefore important to assess and monitor gut barrier dysfunction during hepatic disease. We review methods to assess intestinal barrier disruption and discuss advantages and disadvantages. We will in particular focus on methods that we have used to measure increased intestinal permeability and bacterial translocation in experimental liver disease models.

摘要

肝脏疾病常常与肠道通透性增加有关。肠道屏障的破坏会使微生物产物和活菌从肠腔转移至肠外器官。来自肠道的大部分静脉血会引流至门静脉循环,这是肝脏双重血液供应的一部分。因此,肝脏是人体中第一个不仅会接触到吸收的营养物质,还会接触到源自肠道的细菌和病原体相关分子模式(PAMP)的器官。长期暴露于升高水平的PAMP与肝脏疾病早期的疾病进展以及晚期(肝硬化)的感染性并发症有关。因此,在肝脏疾病期间评估和监测肠道屏障功能障碍非常重要。我们回顾了评估肠道屏障破坏的方法,并讨论了其优缺点。我们将特别关注我们在实验性肝脏疾病模型中用于测量肠道通透性增加和细菌移位的方法。

相似文献

1
Methods to determine intestinal permeability and bacterial translocation during liver disease.
J Immunol Methods. 2015 Jun;421:44-53. doi: 10.1016/j.jim.2014.12.015. Epub 2015 Jan 13.
2
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
J Hepatol. 2019 Dec;71(6):1126-1140. doi: 10.1016/j.jhep.2019.06.017. Epub 2019 Jul 8.
3
Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature.
Liver Int. 2013 Nov;33(10):1457-69. doi: 10.1111/liv.12271. Epub 2013 Jul 23.
4
Gut-liver axis signaling in portal hypertension.
World J Gastroenterol. 2019 Oct 21;25(39):5897-5917. doi: 10.3748/wjg.v25.i39.5897.
5
Role of the gut in multiple organ failure: bacterial translocation and permeability changes.
World J Surg. 1996 May;20(4):411-7. doi: 10.1007/s002689900065.
6
Gut microbiota changes and chronic hepatitis C virus infection.
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):813-819. doi: 10.1080/17474124.2017.1343663. Epub 2017 Jun 23.
7
High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function.
Gastroenterology. 2020 Nov;159(5):1807-1823. doi: 10.1053/j.gastro.2020.07.003. Epub 2020 Jul 9.
9
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
Gastroenterology. 2020 Sep;159(3):849-863. doi: 10.1053/j.gastro.2020.04.077. Epub 2020 Jun 20.
10
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.

引用本文的文献

1
The emerging relationship between mucosal-associated invariant T cell populations and the onset and progression of type 1 diabetes.
Front Immunol. 2025 Jun 18;16:1602934. doi: 10.3389/fimmu.2025.1602934. eCollection 2025.
2
Association of pathotypes with fecal markers of enteropathy and nutritional status among underweight adults in Bangladesh.
Front Cell Infect Microbiol. 2025 Apr 10;15:1553688. doi: 10.3389/fcimb.2025.1553688. eCollection 2025.
3
Host-microbiota interactions in the infant gut revealed by daily faecal sample time series.
Microbiome Res Rep. 2024 Dec 27;4(1):13. doi: 10.20517/mrr.2024.45. eCollection 2025.
4
Gut cannabinoid receptor 1 regulates alcohol binge-induced intestinal permeability.
eGastroenterology. 2025 Feb 12;3(1):e100173. doi: 10.1136/egastro-2024-100173. eCollection 2025 Jan.
5
aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption.
World J Gastroenterol. 2025 Mar 14;31(10):101014. doi: 10.3748/wjg.v31.i10.101014.
6
Understanding Predictors of Crohn's Disease: Determinants of Altered Barrier Function in Pre-Disease Phase of Crohn's Disease.
J Can Assoc Gastroenterol. 2024 Jan 20;7(1):68-77. doi: 10.1093/jcag/gwad052. eCollection 2024 Feb.
7
Looking Inside of the Intestinal Permeability Regulation by Protein-Derivatives from Bovine Milk.
Mol Nutr Food Res. 2024 Nov;68(22):e2400384. doi: 10.1002/mnfr.202400384. Epub 2024 Nov 12.
8
Feeding Intolerance-A Key Factor in the Management of Acute Pancreatitis: A Review.
J Clin Med. 2024 Oct 24;13(21):6361. doi: 10.3390/jcm13216361.
9
Gut dysbiosis contributes to the development of Budd-Chiari syndrome through immune imbalance.
mSystems. 2024 Sep 17;9(9):e0079424. doi: 10.1128/msystems.00794-24. Epub 2024 Aug 21.

本文引用的文献

2
Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
Gastroenterology. 2015 Jan;148(1):203-214.e16. doi: 10.1053/j.gastro.2014.09.014. Epub 2014 Sep 16.
3
IBD: Faecal calprotectin testing--the need for better standardization.
Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):583-4. doi: 10.1038/nrgastro.2014.154. Epub 2014 Sep 9.
4
Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability.
PLoS One. 2014 Jun 5;9(6):e99256. doi: 10.1371/journal.pone.0099256. eCollection 2014.
5
The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.
Tissue Barriers. 2013 Dec 1;1(5):e27321. doi: 10.4161/tisb.27321. Epub 2013 Dec 10.
6
The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota.
Sci Transl Med. 2014 May 21;6(237):237ra66. doi: 10.1126/scitranslmed.3008618.
7
Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract.
Exp Biol Med (Maywood). 2014 Sep;239(9):1124-34. doi: 10.1177/1535370214529398. Epub 2014 Apr 9.
8
Interactions between the intestinal microbiome and liver diseases.
Gastroenterology. 2014 May;146(6):1513-24. doi: 10.1053/j.gastro.2014.01.020. Epub 2014 Jan 15.
9
Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis.
J Innate Immun. 2014;6(3):263-71. doi: 10.1159/000356454. Epub 2013 Nov 29.
10
Large intestine permeability is increased in patients with compensated liver cirrhosis.
Am J Physiol Gastrointest Liver Physiol. 2014 Jan;306(2):G147-53. doi: 10.1152/ajpgi.00330.2013. Epub 2013 Nov 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验